Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20